title: IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
abstract: Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, younger age of onset as compared with other cancers, local and distant metastases, and lower overall survival. The multidisciplinary management of IBC includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and hormonal therapy in hormone receptor-positive disease. Pathological complete response represents an important prognostic factor suggesting IBC as the ideal in-vivo model for therapeutic development. Molecular subtyping demonstrated higher frequency of basal-like an HER2 disease in IBC compared with non-IBC indicating the areas of novel therapeutic interventions. The prospective testing of HER2-targeted therapies (eg, trastuzumab and lapatinib) demonstrated the validity of this concept and the potential to change the outcome of this aggressive disease.
authors.affiliation: Department of Medical Oncology, Dubai Hospital, United Arab Emirates (SD); Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA (MC).
authors.forename: Shaheenah
authors.initials: S
authors.lastname: Dawood
authors.affiliation: Department of Medical Oncology, Dubai Hospital, United Arab Emirates (SD); Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA (MC). Massimo.Cristofanilli@jefferson.edu.
authors.forename: Massimo
authors.initials: M
authors.lastname: Cristofanilli
mesh_terms: D000077716:Afatinib; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000379:methods*; D020360:Neoadjuvant Therapy / Q000379:methods*; D017063:Outcome Assessment, Health Care / Q000379:methods; D000077544:Panitumumab; D011379:Prognosis; D011446:Prospective Studies; D011799:Quinazolines / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012074:Remission Induction; D016019:Survival Analysis; D000068878:Trastuzumab / Q000627:therapeutic use
chemical_list: D000077716:Afatinib; D000911:Antibodies, Monoclonal; D000068258:Bevacizumab; D000077544:Panitumumab; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab